Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.63 |
| ▸ | EBP | Q15125 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ESRRG | P62508 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19643767 | 1.00 | ESR1 (0.63) | ESR1ESR2EBPSIGMAR1BCHE | |
| SCHEMBL19644197 | 0.90 | EBP (0.56) | ESR1ESR2EBPSIGMAR1BCHE | |
| SCHEMBL22773360 | 0.90 | EBP (0.56) | ESR1ESR2EBPSIGMAR1BCHE | |
| SCHEMBL19642705 | 0.90 | EBP (0.56) | ESR1ESR2EBPSIGMAR1BCHE | |
| SCHEMBL19642759 | 0.88 | BCHE (0.64) | ESR1ESR2EBPSIGMAR1BCHE | |
| SCHEMBL19642760 | 0.88 | BCHE (0.64) | ESR1ESR2EBPSIGMAR1BCHE | |
| SCHEMBL4693255 | 0.83 | ESR1 (0.70) | ESR1ESR2EBPSIGMAR1MAOB | |
| SCHEMBL22773260 | 0.82 | BCHE (0.65) | ESR1EBPSIGMAR1BCHEACHE | |
| SCHEMBL19642914 | 0.82 | BCHE (0.65) | ESR1EBPSIGMAR1BCHEACHE | |
| SCHEMBL11854557 | 0.78 | ESR1 (0.52) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2024-07-25 | — | — | US | claimed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | claimed |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-12-17 | — | — | US | claimed |
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2024-07-25 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | GAA, GBA1, GBA2 | ESR1 3412/4885ESR2 2929/4885EBP 2105/4885 |
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | GAA, GBA1, GBA2 | ESR1 3412/4885ESR2 2929/4885EBP 2105/4885 |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | GAA, GBA1, GBA2 | ESR1 3705/4885ESR2 3237/4885EBP 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.